


Our sponsors:



ONCOBELL

2018

1st International Symposium

BARCELONA | SEPTEMBER 20-21

Auditorium. Bellvitge University Hospital.

An international symposium to introduce Oncobell, a new cancer research program within the Bellvitge Biomedical Research Institute (IDIBELL).



<http://oncobellsymposium.idibell.cat>

Thursday 20th

- 09:00 – 09:45 **Registration**
- 09:45 – 10:00 **Welcome**
- 10:00 – 10:50 **KEYNOTE LECTURE.**
 Chaired by **Ramón Salazar**, IDIBELL
Exploiting vulnerabilities of drug-resistant cancer.
René Bernards, NKI, Amsterdam, Netherlands.
- 10:50 – 11:20 **Coffee Break**
- 11:20 – 13:40 **BRISTOL-MYERS SQUIBB SESSION: CLINICAL RESEARCH.**
 Chaired by **Josep M^a Piulats**, IDIBELL.
The Impact of the Check Point Inhibition Strategies in the Treatment of Hematological Malignancies.
Eva Domingo-Domènech, IDIBELL, Barcelona, Spain.
Harnessing the personalized antitumor T-cell response to treat cancer.
Alena Gros, VHIO, Barcelona, Spain.
Potential and limitations of oncolytic adenoviruses.
Ramón Alemany, IDIBELL, Barcelona, Spain.
Developing a CART19 under "academic conditions". How far can we drive it?.
Manel Juan, Hospital Clinic, Barcelona, Spain.
- 13:40 – 14:40 **Lunch**
- 14:40 – 17:00 **GENETICS OF CANCER.**
 Chaired by **Laura Valle**, IDIBELL.
Genetic susceptibility of colorectal cancer.
Victor Moreno, IDIBELL, Barcelona, Spain.
Clinical impact of genomic studies in chronic lymphocytic leukemia.
Elías Campo, IDIBAPS, Barcelona, Spain.
The challenge of interpreting variants of unknown significance.
Gabriel Capellà, IDIBELL, Barcelona, Spain.
Cross-species analysis of gene regulatory networks in metastatic prostate cancer.
Àlvaro Aytés, IDIBELL, Barcelona, Spain.

Friday 21st

- 09:00 – 11:20 **TARGETING OF SIGNALING PATHWAYS.**
 Chaired by **Cristina Muñoz-Pinedo**, IDIBELL.
Insights into mechanisms of prostate cancer resistance.
Mark Rubin, Bern University, Bern, Switzerland.
Immune evasion and metastasis in colorectal cancer.
Eduard Batlle, IRBB, Barcelona, Spain.
The rationale for targeting TGF-beta in hepatocellular carcinoma.
Isabel Fabregat, IDIBELL, Barcelona, Spain.
Targeting the IRBC in c-Myc driven tumors.
George Thomas, IDIBELL, Barcelona, Spain.
- 11:20 – 12:20 **Poster Session and Coffee Break**
- 12:20 – 13:20 **POSTERS HIGHLIGHTS**
The immune response: radio- and immuno-therapy. **Miguel Angel Berenguer**, IDIBELL.
Liquid Biopsy. **Gabriel Capellà**, IDIBELL.
Experimental therapeutics. **Ernest Nadal**, IDIBELL.
Other topics will be considered.
- 13:20 – 14:10 **KEYNOTE LECTURE.**
 Chaired by **Oriol Casanovas**, IDIBELL
Epigenetic signaling pathways controlling invasion and metastasis.
Douglas Hanahan, ISREC, Lausanne, Switzerland.
- 14:10 – 15:00 **Lunch**
- 15:00 – 16:45 **DRUG RESISTANCE AND MICROENVIRONMENT.**
 Chaired by **Mariona Graupera**, IDIBELL.
LIF and the innate immune response. Linking embryology and cancer.
Joan Seoane, VHIO, Barcelona, Spain.
Resistance to Antiangiogenic Therapies by Metabolic Escape via Nucleotide Catabolism.
Oriol Casanovas, IDIBELL, Barcelona, Spain.
Understanding sarcomas: a path to a successful treatment.
Òscar Martínez-Tirado, IDIBELL, Barcelona, Spain.
- 16:45 – 17:35 **RAMÓN ARECES LECTURE:**
 Chaired by **George Thomas**, IDIBELL
Cell Signaling by Receptor Tyrosine Kinases; From Basic Principles to Cancer Therapy.
Joseph Schlessinger, Yale University, New Haven, USA.
- 17:35 – 17:45 **Closing remarks**